FDA Clearance Tracker · DEN200072
Lumipulse G ß-Amyloid Ratio (1-42/1-40)
Last checked: Nov 19, 2026Latest source record: May 4, 2022 (this decision)Source: openFDAMethods & limitations
Decided
May 4, 2022
De Novo granted
Time to decision
530 days
Received Nov 20, 2020. Calendar days, including time FDA spent waiting on the applicant.
Pathway
De Novo
Direct
Device class
Class II
The decision
- FDA number
- DEN200072
- Device name
- Lumipulse G ß-Amyloid Ratio (1-42/1-40)
- Applicant
- Fujirebio Diagnostics,Inc.
- Applicant location
- Malvern, PA
- Received
- Nov 20, 2020
- Decided
- May 4, 2022
- Decision
- De Novo granted
- Submission type
- Direct
Device type
- Device class
- Class II
- Regulation
- 21 CFR 866.5840
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- FDA granted this as a De Novo request, which means it created a new device type. There was no existing device to compare it to.
- It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).
Source documents
- FDA database record for DEN200072
- Decision summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
Other decisions for Fujirebio Diagnostics,Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K250925 · Decided Dec 16, 2025 · 264 days after receipt
Device type: Cytokeratin Fragments 21-1 Eia Kit (OVK) · Laboratory Medicine & Pathology
- Lumipulse G pTau217/ß-Amyloid 1-42 Plasma RatioBreakthrough510(k)
K242706 · Decided May 16, 2025 · 249 days after receipt
Device type: Immunoassay Blood Test For Amyloid Pathology Assessment (SET) · Laboratory Medicine & Pathology
- Lumipulse G CA15-3510(k)
K192524 · Decided Sep 4, 2020 · 357 days after receipt
Device type: System, Test, Immunological, Antigen, Tumor (MOI) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.